CHROMOGENIC HER-2/NEU GENE AMPLIFICATION ASSAY

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$0.00
Award Year:
2002
Program:
STTR
Phase:
Phase I
Contract:
2R42CA083618-02
Award Id:
59922
Agency Tracking Number:
CA083618
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
NANOPROBES, INC., 95 HORSEBLOCK RD, YAPHANK, NY, 11980
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
RICHARDPOWELL
(919) 845-6324
RPOWELL@NANOPROBES.COM
Business Contact:
JAMESHAINFELD
(631) 205-9490
HAINFELD@NANOPROBES.COM
Research Institute:
CLEVELAND CLINIC FOUNDATION

CLEVELAND CLINIC FOUNDATION
CLEVELAND, OH, 44195

Domestic nonprofit research organization
Abstract
Overexpression of the Her-2/neu protein and amplification of the Her-2/neu gene are are the most widely accepted prognostic indicator of aggressive malignant behavior of invasive breast carcinoma. Accurate detection of Her-2/neu overexpression is critical in identifying patients suitable for serotherapy with humanized monoclonal antibody (Herceptin). Fluorescence in situ hybridization (FISH) has been found to be more accurate than immunohistochemical staining. A chromogenic in situ hybridization assay has been developed to detect amplification of the Her-2/neu gene in paraffin-embedded invasive breast carcinoma sections. Unlike FISH, which requires fluorescent optics not routinely available in many pathology laboratories, the assay is read in the conventional brightfield microscope. Detection is based on autometallographically enhanced Nanogold, a highly sensitive method giving a dense black signal, fully compatible with commonly used stains. Excellent concordance was found with FISH, histologic grading and mRNA:rnRNA hybridization for a series of 101 breast carcinomas. We now propose to add a secondary assay for chromosome 17 polysotomy, rnRNA expression or concomitant oncoprotein detection as an internal control to resolve borderline amplification cases. After design optimization, it will be ported to an automated slide staining instrument. Once performance is optimized, multi-center clinical trials will be conducted to support application for pre-market approval.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government